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It is now just over 15 years ago that the
VEGF gene was cloned, and already anti-
VEGF antibodies have been approved to
inhibit angiogenesis as a treatment for
colorectal cancer (Hurwitz et al., 2004). In
spite of this rapid leap forward from bench
to bedside, our ability to monitor—or even
predict—the efficacy of novel antiangio-
genic compounds has not progressed at
the same pace. This poses a formidable
medical problem, as more than 300
angiogenesis inhibitors have now been
identified, of which 80 are currently being
tested in clinical trials (Park et al., 2004).
Several surrogate markers of angiogene-
sis have been considered, but few have
proven to be clinically useful. In this issue
of Cancer Cell, Shaked and colleagues
(Shaked et al., 2005) report that the levels
of circulating endothelial cells (CECs) and
circulating endothelial progenitor cells
(CEPs) vary greatly among animals with
different genetic constitution, but correlate
well with the degree of tumor angiogene-
sis or the response to angiostatic therapy
(Figure 1). Moreover, antiangiogenic ther-
apy can be optimized by monitoring CECs
and CEPs.These exciting results suggest
that the kinetics of these cells in peripher-
al blood are useful surrogate markers of
pathological angiogenesis and are likely
to positively impact the further clinical
development and application of antiangio-
genic therapies.
Historically, blood vessels in tumors
were believed to grow only via sprouting
of preexisting vessels—a process termed
angiogenesis. However, less than 10
years ago, circulating endothelial prog-
enitor cells derived from the bone mar-
row were proposed to contribute to the
formation of new vessels in tumors—a
process termed adult vasculogenesis
(Asahara et al., 1997). Preclinical trials in
animal models, in which genetically
marked donor bone marrow cells were
transplanted into lethally irradiated
hosts, indicated that, depending on the
tumor type, bone marrow fraction, and
method of analysis, incorporation of
CEPs into tumor vessels varied from less
than 1% to up to 50% of new endothelial
cells. While the mere presence of CEPs
in vessels may suggest that they con-
tribute to vessel growth, this finding does
not establish their functional importance.
An interesting question is whether,
and to what extent, CEPs functionally
contribute to vessel growth in health 
and disease. Although bone marrow
transplantation rescues impaired tumor
angiogenesis in mice lacking inhibitors 
of differentation (Id), PlGF, or eNOS
(Carmeliet et al., 2001; Rafii et al., 2002),
extrapolation of such rescue experi-
ments should be done cautiously, as the
predominant angiogenic mechanism of
endothelial cell sprouting was crippled 
in these mice. Another complication is 
that often similar signals (VEGF, PlGF,
angiopoietins) regulate endothelial cell
sprouting and CEP recruitment and,
thus, selective inhibitors cannot be easily
used to identify their relative contribu-
tion. However important biologically, the
question to what extent CEPs functional-
ly contribute to tumor angiogenesis is not
affecting their use as surrogate markers.
Why do we need surrogate markers
to monitor antiangiogenic therapy, and
could we not simply administer the maxi-
mal tolerable dose to cancer patients? In
part, because “the dose makes the poi-
son,” as Paracelsus stated over 400
years ago. Intuitively, one might reason
that “the more vessels that can be
induced to regress, the more efficacious
the angiostatic therapy would be.”
However, elimination of the entire tumor
vascular network will impair vascular
delivery of cytotoxic drugs and, thus, an
optimal angiostatic regimen is required
to “normalize” the density and shape of
tumor vessels for maximal cytotoxic drug
delivery (Jain, 2001). In addition, a
supramaximal dose of an angiostatic
compound may induce undesired side
effects by attacking the quiescent vascu-
lature in the rest of the body—this will
become increasingly relevant when
more and more cancer patients are treat-
ed at earlier stages during their disease
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The first angiogenesis inhibitor has recently been approved for cancer treatment. Nonetheless, optimizing the dose of
novel angiogenesis inhibitors remains a formidable challenge—primarily because we lack reliable surrogate markers of
tumor angiogenesis. In this issue, Shaked et al. provide evidence that the levels of circulating endothelial precursor cells
(CEPs), which contribute to the formation of tumor vessels, are genetically predetermined and regulated by angiogenic fac-
tors, and reflect the antitumor efficacy of angiogenesis inhibitors. These findings highlight the potential usefulness of
CEPs as a surrogate marker to monitor and adjust antiangiogenic therapy.
Figure 1. CEP levels monitor tumor angio-
genesis and growth
Left panel: In healthy mice, a low number of
circulating endothelial progenitors (CEPs) are
mobilized from the bone marrow (BM) into the
peripheral blood (PB). Middle panel: In tumor-
bearing mice, increased numbers of CEPs
correlate with enhanced tumor angiogenesis
and growth. CEP levels can be used as a sur-
rogate marker to monitor tumor angiogenesis
and to adjust the dose of angiogenesis
inhibitors. Right panel: Treatment of tumor-
bearing mice with angiogenesis inhibitors
reduces CEP levels in the peripheral blood
and shrinks the tumor.
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course. Optimizing angiostatic therapy is
thus of great medical importance, and
will likely determine the future success of
angiogenesis inhibition.
Currently, the degree of angiogene-
sis or the response to angiostatic com-
pounds is evaluated indirectly by
measuring the microvascular density,
size, or interstitial fluid pressure in
tumors, or by determining the levels of
angiogenic molecules (such as VEGF) in
the plasma or in tumor tissue. These
parameters are not always predictive
and/or technically challenging in daily
hospital practice. In addition, current
technology to image the disorganized
and highly permeable tumor microvascu-
lature is still in a preclinical phase of
development (McDonald and Choyke,
2003). There is thus an urgent need to
discover novel and more reliable surro-
gate markers of tumor angiogenesis. In a
recent study, Willett et al. reported that
treatment of colorectal cancer patients
with an anti-VEGF antibody not only
blocked tumor growth but also lowered
the numbers of CEPs—thus suggesting
that CEPs might be surrogate markers of
angiostatic therapy (Willett et al., 2004).
In a series of elegant genetic and
pharmacological studies, Shaked et al.
provide further evidence that the levels of
CECs and CEPs could indeed be useful
surrogate markers of tumor angiogensis
(Shaked et al., 2005). First, the authors
showed that CEP levels correlated with
the angiogenic response to VEGF and
bFGF in the avascular cornea and
matrigel plug, taking advantage of the
variable degree of angiogenic responsive-
ness in different mouse strains: mouse
lines which are hyporesponsive to angio-
genic molecules formed few blood ves-
sels and also had low numbers of CEPs,
while the opposite was true for the hyper-
responsive mouse strains. Second, loss
of the angiogenic inhibitor TSP-1 or
genetic upregulation of VEGF or Tie2 ele-
vated CEP levels, while pharmacological
inhibition of TSP-1 or VEGFR-2 lowered
CEP levels in the peripheral blood. Third,
an anti-VEGFR-2 antibody inhibited CEP
levels and tumor growth at a comparable
dose range—the implication of this finding
being that it is possible to select an opti-
mal angiogenesis inhibitor dose for tumor
inhibition by determining the inhibitor
dose that maximally reduces CEP levels.
Fourth, CEP levels seemed to be a gener-
ally applicable surrogate marker, as they
were elevated in tumor-bearing mice and
reduced to background levels using
antiangiogenic drugs—regardless of the
type of tumors (transplanted versus spon-
taneous, solid versus leukemic), angio-
genesis inhibitor, or mouse strain.
Together, these data show that the levels
of cells of endothelial lineage, circulating
in the peripheral blood, correlate with the
degree of angiogenesis in the adult. The
insight that CECs and CEPs are useful
surrogate markers to monitor angiogene-
sis will likely aid future development and
application of antiangiogenic compounds
in the clinic.
Apart from the excitement that these
findings raise, a number of outstanding
issues will need to be resolved in the
future. For instance, will CEP and CEC
levels also vary 20-fold in humans, and
can we identify the genes responsible for
this predisposition? Will these levels be
predictive surrogate markers of angio-
genesis in cancer or ocular or inflamma-
tory disease in humans as well? Do the
levels of circulating cells in the peripheral
blood correlate with the percentage of
CEP-derived cells in growing vessels in
tumors? CEP counts in tumor-bearing
mice and patients are low—will this
assay be sufficiently robust and sensitive
in daily hospital practice, and will most
tumors mobilize sufficient CEPs to be
detected as a surrogate marker? Apart
from cancer, CEP levels may also be
affected by cardiovascular disorders (Hill
et al., 2003)—how specific will these sur-
rogate markers turn out to be? The find-
ings that CEP levels can be used as
surrogate markers also raise the intrigu-
ing question whether hematopoietic
stem cells, which also affect tumor
angiogenesis, will have any value as sur-
rogate markers as well.
Notwithstanding these outstanding
questions, the authors’ findings provide a
strong rationale to further evaluate the
usefulness of measuring CEC and CEP
levels as surrogate markers for tumor
angiogenesis and its treatment.
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